These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12548114)

  • 21. Cost effectiveness and projected national impact of colorectal cancer screening in France.
    Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
    Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-effectiveness analysis on colorectal cancer screening program].
    Huang QC; Ye D; Jiang XY; Li QL; Yao KY; Wang JB; Jin MJ; Chen K
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jan; 38(1):65-68. PubMed ID: 28100379
    [No Abstract]   [Full Text] [Related]  

  • 23. Mathematical models and cost-effective screening strategies for colorectal cancer.
    Smith RA
    CMAJ; 2010 Sep; 182(12):1283-4. PubMed ID: 20713572
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cost of a mass screening program for colorectal cancer using the occult blood test].
    Arveux P; Faivre J; Bedenne L; Durand G; Milan C; Milan C
    Gastroenterol Clin Biol; 1992; 16(6-7):547-51. PubMed ID: 1526416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.
    Jouve JL; Remontet L; Dancourt V; Lejeune C; Benhamiche AM; Faivre J; Esteve J
    Br J Cancer; 2001 Jun; 84(11):1477-81. PubMed ID: 11384097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered.
    Lee KS; Park EC
    Cancer Res Treat; 2016 Jul; 48(3):1010-9. PubMed ID: 26727714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Markov's modeling for screening strategies for colorectal cancer.
    Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
    Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal occult blood test for colorectal cancer screening.
    Strul H; Arber N
    Ann Oncol; 2002 Jan; 13(1):51-6. PubMed ID: 11863111
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
    Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
    Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the impact of the screening programme for colorectal cancer in the UK.
    Parkin DM; Tappenden P; Olsen AH; Patnick J; Sasieni P
    J Med Screen; 2008; 15(4):163-74. PubMed ID: 19106256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Colorectal cancer mass screening: present and future].
    Bretagne JF; Manfredi S; Heresbach D
    Presse Med; 2007; 36(7-8):1054-63. PubMed ID: 17481847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting the effectiveness of the Finnish population-based colorectal cancer screening programme.
    Chiu SY; Malila N; Yen AM; Chen SL; Fann JC; Hakama M
    J Med Screen; 2017 Dec; 24(4):182-188. PubMed ID: 28084889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of colorectal cancer screening with fecal occult blood detection.
    Tárraga López PJ; Marín Nieto E; Celada Rodríguez A; García Molinero MJ; García Olmo D; Solera Albero J
    Rev Esp Enferm Dig; 2000 May; 92(5):334-48. PubMed ID: 10927933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.